Biopharma firm Clene reports Q3 net loss of $8.8 mln

Clene

13/11/2025 13:10

Overview

Clene reports Q3 net loss of $8.8 mln, increased from $8.0 mln last year

Cash and cash equivalents total $7.9 mln, runway extended into Q2 2026

Company plans NDA submission for CNM-Au8 in Q1 2026 under accelerated approval

Outlook

Clene plans to submit NDA for ALS treatment in Q1 2026

Company expects first patient dosed in Phase 3 ALS trial in H1 2026

Clene extends cash runway into Q2 2026

Result Drivers

Research and development expenses were $3.5 million for the quarter ended September 30, 2025, compared to $4.5 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$8.78 mln
Q3 Basic EPS
-$0.85
Q3 Income From Operations
-$5.65 mln
Q3 Operating Expenses
$5.66 mln
Q3 Pretax Profit
-$8.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Clene Inc is $30.00, about 68.6% above its November 12 closing price of $9.41

Press Release: ID:nGNXpG9kl

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)